Penumbra Stockholders Approve $14.5B Merger with Boston Scientific

summarizeSummary

Penumbra Inc. stockholders overwhelmingly approved the merger agreement with Boston Scientific, satisfying a key condition for the $14.5 billion acquisition.

check_boxKey Events

• Merger Agreement Approved

  Penumbra's stockholders voted to adopt the Agreement and Plan of Merger with Boston Scientific Corporation, with 28,564,786 votes in favor.

• Key Merger Condition Met

  The stockholder approval satisfies a critical condition for the consummation of the $14.5 billion merger.

• Remaining Conditions Pending

  Consummation of the merger is still subject to other closing conditions, including antitrust and foreign investment approvals.

auto_awesomeAnalysis

This 8-K formally reports the results of the special meeting where Penumbra's stockholders voted to adopt the merger agreement with Boston Scientific Corporation. The overwhelming approval of the merger proposal (over 99% of votes cast) is a critical step towards the consummation of the previously announced $14.5 billion acquisition, removing a significant shareholder-related hurdle. This filing adds specific vote details to the approval previously communicated via a 425 filing today. While this approval satisfies a major condition, the merger remains subject to other closing conditions, including regulatory clearances such as the Hart-Scott-Rodino Antitrust Improvements Act. Investors should monitor progress on these remaining conditions for the finalization of the deal.